Email updates

Keep up to date with the latest news and content from Molecular Cytogenetics and BioMed Central.

Open Access Letter to Editor

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Neda Mosakhani1, Satu Mustjoki2 and Sakari Knuutila1*

Author Affiliations

1 Department of Pathology, Haartman Institute, and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

2 Hematology Research Unit Helsinki, Department of Medicine, Division of Hematology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

For all author emails, please log on.

Molecular Cytogenetics 2013, 6:27  doi:10.1186/1755-8166-6-27

Published: 16 July 2013

Abstract

The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.

Keywords:
miRNA; CML; Imatinib response